Abstract VARS2 encodes a mitochondrial aminoacyl-tRNAsynthetase. Mutations in VARS2 have recently been identified as a cause of mitochondrial encephalomyopathy in three individuals. However, clinical information remained scarce. Exome sequencing lead us to identify compound heterozygous pathogenic VARS2 variants in a boy presenting with severe lactic acidosis, hypertrophic cardiomyopathy, epilepsy, and abnormalities on brain imaging including hypoplasia of corpus callosum and cerebellum as well as a massive lactate peak on MR-spectroscopy. Studies in patient-derived fibroblasts confirmed the functional relevance of the identified VARS2 variants. Our report expands the phenotypic spectrum associated with this rare mitochondrial defect, in that VARS2 deficiency may also cause severe neonatal presentations with cardiac involvement and structural brain abnormalities.
Introduction
Mitochondrial disorders are caused by inherited defects of the pyruvate oxidation route. The core of this pathway consists of the oxidative phosphorylation (OXPHOS) system Components of this system are encoded by the nuclear and the mitochondrial genome. Aside from mitochondrial DNAencoded tRNAs and rRNAs, the mitochondrial translation apparatus consists of over 100 nuclear-encoded proteins, which are synthesized in the cytoplasm and then imported into the mitochondrial matrix (Smits et al. 2010) . These include, amongst others, mitochondrial aminoacyl-tRNA-synthetases (mt-aaRS), which catalyze the ligation of amino acids to their specific tRNAs. Deficiency of the nuclear-encoded valyltRNA-synthetase due to bi-allelic variants in the encoding VARS2 gene has recently been described in three individuals with mitochondrial encephalopathies (Diodato et al. 2014; Pronicka et al. 2016; Taylor et al. 2014) . However, little clinical information was given, leaving the phenotype of VARS2 deficiency largely uncharacterized.
Here, we present a neonate with a novel VARS2 variant and neonatal mitochondrial encephalopathy with structural brain abnormalities, hypertrophic cardiomyopathy and severe lactic acidosis. We present detailed clinical data and further delineate the phenotype.
Materials & methods

Genetic studies
Exome sequencing was performed as described previously ) using a SureSelect Human All Exon Kit (Agilent, 50 Mb V5) for enrichment and a HiSeq2500 (Illumina) for sequencing of prepared libraries. BWA (version 0.5.87.5) was used for read alignment to the human reference assembly (hg19). Genetic variation was detected using SAMtools (v 0.1.18), PINDEL (v 0.2.4 t), and ExomeDepth (v1.0.0). Variant confirmation and carrier testing was done by Sanger sequencing. Oligonucleotide sequences and PCR conditions are provided upon request.
Cell culture
Patient and control skin fibroblasts were cultured in DMEM medium (Gibco). The media were supplemented with 10 % (v/v) of fetal calf serum and 1 % penicilln/ streptomycin (v/v).
Sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting/immunodetection
SDS-PAGE and western blotting/immunodetection were performed as previously described (Baertling et al. 2015a) . 25 μg of fibroblast whole cell protein were separated in a ready-touse 4-12 % SDS-PAGE gradient gel (Invitrogen). Proteins were transferred to a 0.2 μm nitrocellulose membrane (Bio Rad). Membranes were blocked and incubated with primary antibodies against VARS2 (Proteintech; 1:500) or GAPDH (Applied Biosystems) overnight at 4°C, followed by washing and incubation with donkey anti rabbit IgG HRP (NA934V; GE Healthcare) and sheep anti mouse IgG HRP (NA931V GE Healthcare) as secondary antibodies for an hour at room temperature.
Results
Case report
The male patient is the second child of non-consanguineous parents of Greek origin and was born after an uneventful pregnancy at a gestational age of 39 weeks. Family history was unremarkable, especially no metabolic disorders, spontaneous abortions or early deaths. The patient's postnatal adaptation was normal with APGAR scores of 8, 9 and 9. He was small for gestational age (weight: 2960 g, 8th percentile).
On the second day of life, he developed lactic acidosis with blood lactate levels of up to 28 mmol/L (NR 0.5-1.6 mmol/L) and pronounced urinary lactate and pyruvate excretion. Further metabolic work-up revealed excretion of 2-Oxoisocaproic acid and 2-Oxo-3-methyl-N-valeric acid. Both are intermediates of mitochondrial branched-chain-amino-acid catabolism. Free carnitine levels were reduced but no abnormal acylcarnitine profiles were detected. Alanine blood levels were increased.
The acidosis was treated with sodium bicarbonate. Levocarnitine was supplemented due to low free carnitine levels. Additionally, the patient received riboflavin, thiamine, coenzyme Q 10 , and biotin in accordance with recently published recommendations (Danhauser et al. 2015) . The metabolic acidosis was accompanied by global respiratory insufficiency, which necessitated intubation and mechanical ventilation for four weeks.
Neurological symptoms included increased muscle tone and focal epileptic seizures with clonic jerks of the facial muscles associated with apnea. Electroencephalography (EEG) revealed epileptic abnormalities resembling burst suppression patterns. Brain magnetic resonance imaging (MRI) at the age of five weeks showed hypoplasia of the corpus callosum and the cerebellum (Fig. 1a) accompanied by edema of the brain stem and the frontal white matter. The basal ganglia displayed hyperintensities in T1-weighted images and a marked lactate peak in magnetic resonance spectroscopy (MRS; Fig. 1b) .
Echocardiographic examinations in the newborn period revealed a severe hypertrophic non-obstructive cardiomyopathy with left-ventricular non-compaction and moderate left ventricular dilation (Fig. 1c) . Left ventricular function was markedly reduced with a shortening fraction of 17 % and an ejection fraction of 31 %. Treatment included milrinon, bisoprolol, and furosemide. Aspirin was given due to the risk of intraventricular thrombosis.
At the age of five weeks, metabolic crisis eventually resolved and progression of cardiomyopathy stopped. At the current age of 5 months, the child is severely microcephalic and suffers from epilepsy, spastic movement disorder, and hypertrophic cardiomyopathy. He shows exotropia and does not fixate or follow objects.
Exome sequencing identifies clinically relevant VARS2 variants
Exome sequencing yielded an average 154-fold coverage with >98 % of target sequences being covered >20-fold. A search for predictively compound heterozygous or homozygous rare (MAF > 0.1 % in 8000 in-house control exomes) nonsynonymous variants prioritized 15 genes. Of these genes, four (LRP5, STAT2, FMN2, and VARS2) are listed in OMIM with a phenotype key of 3 and have been associated with autosomal recessive inherited phenotypes. VARS2 (NM_001167734.1) was the only gene known to be associated with mitochondrial dysfunction. Sanger sequencing confirmed the two missense variants in a compound heterozygous state with the variant c.601C > T, p.(Arg201Trp) being located on the paternal and the c.1100C > T, p.(Thr367Ile) variant on the maternal allele (Fig. 1d) . Both variants are very rare and are listed 3 times only in a heterozygous state in 121,412 (MAF 0.0024 %) and 116,086 (MAF 0.0025 %) control alleles, respectively (Exome Aggregation Consortium (ExAC), Cambridge, MA, USA (URL: http://exac.broadinstitute.org) [02/2016] ). The variant c.1100C > T has been previously reported as clinically relevant in a homozygous state in a patient with mitochondrial encephalopathy (Diodato et al. 2014 ). To our knowledge, the c.601C > T has not been associated with human disease to date. Different prediction algorithms rate this variant as likely functionally relevant (SIFT: score 0; PolyPhen2: probably damaging, CADD: score 36).
VARS2 protein levels are reduced in patient fibroblasts
In order to confirm VARS2 deficiency on protein level, western blotting and immunodetection were performed. In the patient's skin fibroblasts a > 70 % decrease in VARS2 protein levels was observed in comparison to fibroblasts of a healthy control subject (Fig. 1e) , thereby corroborating the functional relevance of the identified VARS2 variants.
Discussion
Aside from our report, three further patients with VARS2 variants have been described. The first report includes a patient with a homozygous missense variant (c.1100C > T, p. Thr367Ile) who presented with facial dysmorphisms, microcephaly, and psychomotor delay soon after birth (Diodato et al. 2014) . At four years of age, he developed epilepsy. Brain MRI displayed hyperintense lesions in the periventricular regions, the insulae, and the frontotemporal right cortex. The second patient had multiple OXPHOS complex deficiency and a compound heterozygous varia n t s i n VA R S 2 ( c . . At disease onset, the patient was younger than one year and disease manifestation included affections of central nervous system and skeletal muscles but not of the heart or liver. No further details were given. The third patient displayed compound heterozygous variants including one described above (Pronicka et al. 2016) . After being born at a gestational age of 40 weeks with a birth weight of 3420 g, he suffered from neonatal onset disease with stridor, lactic acidosis and cardiomyopathy. No further details were given. Fig. 1 Our report widens the clinical phenotype of VARS2 deficiency with severe neonatal lactic acidosis, cardiomyopathy, structural brain abnormalities as well as early-onset epileptic encephalopathy. Furthermore, hypoplasia of the corpus callosum and especially cerebellar hypoplasia suggest a fetal disease onset. Despite a rather severe disease course in the neonatal period, a stabilization of previously progressive cardiomyopathy took place and metabolic crisis resolved at the age of five weeks. Interestingly, in other mitochondrial translation defects such as EARS2 variants (Danhauser et al. 2016; Steenweg et al. 2012) , similar spontaneous disease stabilizations were observed. The hypothesis of a Bvulnerable periodf or disease onset was proposed (Steenweg et al. 2012) . In general, neonatal adaptation to extrauterine life constitutes a stress situation, which frequently causes acute decompensation in children with severe mitochondrial diseases. Adequate therapy (e.g. caloric supply, buffer therapy, etc.) might help to stabilize the disease course (Danhauser et al. 2015) .
Our report adds VARS2 to the list of genes that should be considered in the differential diagnosis of neonatal mitochondrial encephalocardiomyopathies similar to defects in mitochondrial translation elongation factors or mitochondrial ribosomal protein genes (Baertling et al. 2015a; Baertling et al. 2015b; Distelmaier et al. 2015; Kopajtich et al. 2014) . Additional clinical reports are required to further define the phenotypic spectrum and the disease course associated with VARS2 deficiency.
